Cargando…

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients

BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evid...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan, Gan, Qinyi, Lai, Rongtao, Wang, Weijing, Guo, Simin, Sheng, Zike, Chen, Lu, Guo, Qing, Cai, Wei, Wang, Hui, Zhao, Gangde, Cao, Zhujun, Xie, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801606/
https://www.ncbi.nlm.nih.gov/pubmed/35111690
http://dx.doi.org/10.3389/fcimb.2021.733348
_version_ 1784642498934603776
author Huang, Yan
Gan, Qinyi
Lai, Rongtao
Wang, Weijing
Guo, Simin
Sheng, Zike
Chen, Lu
Guo, Qing
Cai, Wei
Wang, Hui
Zhao, Gangde
Cao, Zhujun
Xie, Qing
author_facet Huang, Yan
Gan, Qinyi
Lai, Rongtao
Wang, Weijing
Guo, Simin
Sheng, Zike
Chen, Lu
Guo, Qing
Cai, Wei
Wang, Hui
Zhao, Gangde
Cao, Zhujun
Xie, Qing
author_sort Huang, Yan
collection PubMed
description BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evidence of the fibrotic effect of NAFLD or NASH in chronic hepatitis B virus (HBV) infection remains lacking. We aimed to reveal the influence of concurrent histologically proven fatty liver diseases in fibrogenesis with chronic HBV infection. METHODS: We performed a retrospective cross-sectional study on a liver biopsy population of CHB patients without excessive alcohol intake to evaluate the prevalence of concurrent histologically proven NAFLD or NASH according to the fatty liver inhibition of progression (FLIP) algorithm and its association with the liver fibrosis stage. RESULTS: Among 1,081 CHB patients, concurrent NAFLD was found in 404 patients (37.4%), among whom 24.0% (97/404) have NASH. The presence of NASH was an independent predictor of significant fibrosis (odds ratio (OR), 2.53; 95% CI, 1.52–4.21; p < 0.001) and severe fibrosis (OR, 1.83; 95% CI, 1.09–3.09; p = 0.023) in all patients, as well as in patients with normal alanine aminotransferase (ALT) (predicting significant fibrosis, OR, 2.86, 95% CI, 1.34–6.10; p = 0.007). The presence of lobular inflammation (p < 0.001) or presence of cytological ballooning (p < 0.001), rather than presence of steatosis (p = 0.419), was related with severity of fibrosis in Spearman’s correlation analysis. CONCLUSIONS: Concurrent NAFLD is common in CHB patients, and NASH is an independent risk factor potentiating significant fibrosis by 2.53-fold and severe fibrosis by 1.83-fold. While coping with chronic HBV infection, routine assessment of co-existing NAFLD or NASH is also important.
format Online
Article
Text
id pubmed-8801606
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88016062022-02-01 Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients Huang, Yan Gan, Qinyi Lai, Rongtao Wang, Weijing Guo, Simin Sheng, Zike Chen, Lu Guo, Qing Cai, Wei Wang, Hui Zhao, Gangde Cao, Zhujun Xie, Qing Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUNDS AND PURPOSE: Concurrent non-alcoholic fatty liver disease (NAFLD) in chronic hepatitis B (CHB) patients is a frequent and increasingly concerning problem because of the NAFLD pandemic. Admittedly, NAFLD can progress to non-alcoholic steatohepatitis (NASH) and severe fibrosis. Direct evidence of the fibrotic effect of NAFLD or NASH in chronic hepatitis B virus (HBV) infection remains lacking. We aimed to reveal the influence of concurrent histologically proven fatty liver diseases in fibrogenesis with chronic HBV infection. METHODS: We performed a retrospective cross-sectional study on a liver biopsy population of CHB patients without excessive alcohol intake to evaluate the prevalence of concurrent histologically proven NAFLD or NASH according to the fatty liver inhibition of progression (FLIP) algorithm and its association with the liver fibrosis stage. RESULTS: Among 1,081 CHB patients, concurrent NAFLD was found in 404 patients (37.4%), among whom 24.0% (97/404) have NASH. The presence of NASH was an independent predictor of significant fibrosis (odds ratio (OR), 2.53; 95% CI, 1.52–4.21; p < 0.001) and severe fibrosis (OR, 1.83; 95% CI, 1.09–3.09; p = 0.023) in all patients, as well as in patients with normal alanine aminotransferase (ALT) (predicting significant fibrosis, OR, 2.86, 95% CI, 1.34–6.10; p = 0.007). The presence of lobular inflammation (p < 0.001) or presence of cytological ballooning (p < 0.001), rather than presence of steatosis (p = 0.419), was related with severity of fibrosis in Spearman’s correlation analysis. CONCLUSIONS: Concurrent NAFLD is common in CHB patients, and NASH is an independent risk factor potentiating significant fibrosis by 2.53-fold and severe fibrosis by 1.83-fold. While coping with chronic HBV infection, routine assessment of co-existing NAFLD or NASH is also important. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801606/ /pubmed/35111690 http://dx.doi.org/10.3389/fcimb.2021.733348 Text en Copyright © 2022 Huang, Gan, Lai, Wang, Guo, Sheng, Chen, Guo, Cai, Wang, Zhao, Cao and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Huang, Yan
Gan, Qinyi
Lai, Rongtao
Wang, Weijing
Guo, Simin
Sheng, Zike
Chen, Lu
Guo, Qing
Cai, Wei
Wang, Hui
Zhao, Gangde
Cao, Zhujun
Xie, Qing
Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
title Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
title_full Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
title_fullStr Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
title_full_unstemmed Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
title_short Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
title_sort application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis b patients
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801606/
https://www.ncbi.nlm.nih.gov/pubmed/35111690
http://dx.doi.org/10.3389/fcimb.2021.733348
work_keys_str_mv AT huangyan applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT ganqinyi applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT lairongtao applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT wangweijing applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT guosimin applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT shengzike applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT chenlu applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT guoqing applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT caiwei applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT wanghui applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT zhaogangde applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT caozhujun applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients
AT xieqing applicationoffattyliverinhibitionofprogressionalgorithmandsteatosisactivityandfibrosisscoretoassesstheimpactofnonalcoholicfattyliveronuntreatedchronichepatitisbpatients